目的:目前,角膜失明正在影响全球超过1000万人,并且由于缺乏高质量的移植物,全球仅满足了1.5%的移植需求,因此存在大量未满足的医疗需求。鉴于这场全球健康灾难,研究人员正在开发角膜替代品,可以在体内类似于人类角膜,并替代人类供体组织。因此,本综述通过回顾现有的临床和非临床发现,研究ROCK(Rho相关的含卷曲螺旋蛋白激酶)抑制剂作为一种潜在的角膜创伤愈合(CWH)疗法.方法:系统评价来自PubMed,Scopus,WebofScience,和CWH的谷歌学者,角膜损伤,角膜内皮伤口愈合,岩石抑制剂,法舒地尔,Netarsudil,Ripasudil,Y-27632临床试验,临床研究,案例系列,病例报告,临床前研究,在体内,和体外研究。删除重复项后,所有下载的文章都接受了检查。文献检索包括截至2023年1月的数据。结果:本文总结了ROCK抑制剂在临床和临床前试验中的结果。在临床试验中,各种ROCK抑制剂可改善开角型青光眼患者的CWH,白内障,虹膜囊肿,高眼压,和其他眼部疾病。ROCK抑制剂还通过增加细胞粘附来改善眼部伤口愈合,迁移,和体外和体内增殖。结论:ROCK抑制剂具有抗纤维化作用,抗血管生成,抗炎,和CWH的抗凋亡特性,根据现有的研究。ROCK抑制剂是角膜感染的有效局部治疗方法。Ripasudil,Y-27632,H-1152,Y-39983和AMA0526是一些新的ROCK抑制剂,可能有助于CWH并替代人类供体组织。
Currently, corneal blindness is affecting >10 million individuals worldwide, and there is a significant unmet medical need because only 1.5% of transplantation needs are met globally due to a lack of high-quality grafts. In light of this global health disaster, researchers are developing corneal substitutes that can resemble the human cornea in vivo and replace human donor tissue. Thus, this review examines ROCK (Rho-associated coiled-coil containing protein kinases) inhibitors as a potential corneal wound-healing (CWH) therapy by reviewing the existing clinical and nonclinical findings. The systematic review was done from PubMed, Scopus, Web of Science, and Google Scholar for CWH, corneal injury, corneal endothelial wound healing, ROCK inhibitors, Fasudil, Netarsudil, Ripasudil, Y-27632, clinical trial, clinical study, case series, case reports, preclinical study, in vivo, and in vitro studies. After removing duplicates, all downloaded articles were examined. The literature search included the data till January 2023. This review summarized the results of ROCK inhibitors in clinical and preclinical trials. In a clinical trial, various ROCK inhibitors improved CWH in individuals with open-angle glaucoma, cataract, iris cyst, ocular hypertension, and other ocular diseases. ROCK inhibitors also improved ocular wound healing by increasing cell adhesion, migration, and proliferation in vitro and in vivo. ROCK inhibitors have antifibrotic, antiangiogenic, anti-inflammatory, and antiapoptotic characteristics in CWH, according to the existing research. ROCK inhibitors were effective topical treatments for corneal infections. Ripasudil, Y-27632, H-1152, Y-39983, and AMA0526 are a few new ROCK inhibitors that may help CWH and replace human donor tissue.